To include your compound in the COVID-19 Resource Center, submit it here.

New light on gamma secretase failures in AD

In a study published in Cell Reports this week, researchers from Osaka University added another possible explanation for why gamma secretase/presenilin inhibitors have failed in Alzheimer’s disease trials.

The gamma secretase complex acts downstream of beta-site APP-cleaving enzyme (BACE) in the processing of amyloid precursor protein (APP) to generate beta amyloid, a toxic peptide that forms

Read the full 569 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE